{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T08:22:23Z","timestamp":1740126143526,"version":"3.37.3"},"reference-count":34,"publisher":"Oxford University Press (OUP)","issue":"5","license":[{"start":{"date-parts":[[2024,1,12]],"date-time":"2024-01-12T00:00:00Z","timestamp":1705017600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"DOI":"10.13039\/501100022606","name":"Almirall","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100022606","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,4,17]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Topical agents are an essential component of psoriasis therapy.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Objectives<\/jats:title>\n                  <jats:p>To develop a new version of the patient-reported Patient Benefit Index assessing the importance and achievement of treatment goals in topical psoriasis therapy in adult patients (PBI-TOP).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>Through semi-structured interviews, focus groups and free-text questionnaires, patients reported their needs in topical treatment. Based on qualitative content analysis, items were developed by a consensus group and were refined in cognitive debriefing interviews. A pilot validation assessed the PBI-TOP and convergent criteria [Dermatology Life Quality Index (DLQI); Psoriasis Area and Severity Index (PASI); affected Body Surface Area (BSA)].<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Thirty patients (26\u201372\u2005years, mean 47; 60% male) reported various treatment goals relating to the themes \u2018effectiveness\u2019 and \u2018characteristics of the preparation\u2019. Twenty patients took part in cognitive debriefings (22\u201384\u2005years, mean 50.6, 50% male). There were 154 patients who participated in the pilot validation (18\u201385\u2005years, mean 46.9, 63.6% male). An importance-weighted total score on overall effectiveness and three subscales based on exploratory factor analysis were defined: effectiveness on symptoms, effectiveness on quality of life (QoL), and characteristics of the preparation. All scores showed excellent internal consistency (\u03b1 &amp;gt; 0.9). The global effectiveness score correlated significantly with DLQI (r = \u20130.41), PASI (r = \u20130.32) and BSA (r = \u20130.22). The effectiveness subscales (symptoms; QoL) correlated significantly with DLQI (r = \u20130.41; \u20130.32) and PASI (r = \u20130.27; \u20130.33). The score on characteristics of the preparation correlated significantly with the DLQI (r = \u20130.34).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>The PBI-TOP showed good feasibility and favourable psychometric characteristics in this pilot validation.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/bjd\/ljad484","type":"journal-article","created":{"date-parts":[[2024,1,12]],"date-time":"2024-01-12T07:25:32Z","timestamp":1705044332000},"page":"701-711","source":"Crossref","is-referenced-by-count":0,"title":["Goals and benefits in topical treatment for psoriasis: development and pilot validation of a patient-reported outcomes tool, the Patient Benefit Index for Topical Treatment (PBI-TOP)"],"prefix":"10.1093","volume":"190","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1163-1639","authenticated-orcid":false,"given":"Christine","family":"Blome","sequence":"first","affiliation":[{"name":"Institute for Health Services Research in Dermatology and Nursing (IVDP), University Medical Center Hamburg-Eppendorf (UKE) , Hamburg , Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lennart","family":"H\u00fclswitt","sequence":"additional","affiliation":[{"name":"Institute for Health Services Research in Dermatology and Nursing (IVDP), University Medical Center Hamburg-Eppendorf (UKE) , Hamburg , Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna","family":"Meineke","sequence":"additional","affiliation":[{"name":"Institute for Health Services Research in Dermatology and Nursing (IVDP), University Medical Center Hamburg-Eppendorf (UKE) , Hamburg , Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4026-8728","authenticated-orcid":false,"given":"Matthias","family":"Augustin","sequence":"additional","affiliation":[{"name":"Institute for Health Services Research in Dermatology and Nursing (IVDP), University Medical Center Hamburg-Eppendorf (UKE) , Hamburg , Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0177-1283","authenticated-orcid":false,"given":"Frenz","family":"Ohm","sequence":"additional","affiliation":[{"name":"Institute for Health Services Research in Dermatology and Nursing (IVDP), University Medical Center Hamburg-Eppendorf (UKE) , Hamburg , Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Judith","family":"Rusch","sequence":"additional","affiliation":[{"name":"Institute for Health Services Research in Dermatology and Nursing (IVDP), University Medical Center Hamburg-Eppendorf (UKE) , Hamburg , Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9861-9519","authenticated-orcid":false,"given":"Toni Maria","family":"Janke","sequence":"additional","affiliation":[{"name":"Institute for Health Services Research in Dermatology and Nursing (IVDP), University Medical Center Hamburg-Eppendorf (UKE) , Hamburg , Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2024,1,12]]},"reference":[{"key":"2024041719052917600_ljad484-B1","doi-asserted-by":"crossref","first-page":"m1590","DOI":"10.1136\/bmj.m1590","article-title":"National, regional, and worldwide epidemiology of psoriasis: systematic analysis and modelling study","volume":"369","author":"Parisi","year":"2020","journal-title":"BMJ"},{"key":"2024041719052917600_ljad484-B2","doi-asserted-by":"crossref","first-page":"e047806","DOI":"10.1136\/bmjopen-2020-047806","article-title":"Regional variations and prevalence of psoriasis in Germany from 2010 to 2017: a cross-sectional, spatio-epidemiological study on ambulatory claims data","volume":"11","author":"Andrees","year":"2021","journal-title":"BMJ Open"},{"key":"2024041719052917600_ljad484-B3","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1586\/14737167.2014.914437","article-title":"Quality of life in psoriasis patients","volume":"14","author":"Augustin","year":"2014","journal-title":"Expert Rev Pharmacoecon Outcomes Res"},{"key":"2024041719052917600_ljad484-B4","doi-asserted-by":"crossref","first-page":"2461","DOI":"10.1111\/jdv.16915","article-title":"EuroGuiDerm Guideline on the systemic treatment of psoriasis vulgaris \u2013 Part 1: treatment and monitoring recommendations","volume":"34","author":"Nast","year":"2020","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"2024041719052917600_ljad484-B5","first-page":"376","article-title":"S2k-Leitlinie zum Gebrauch von Pr\u00e4parationen zur lokalen Anwendung auf der Haut (Topika)","volume":"16","author":"Wohlrab","year":"2018","journal-title":"J Dtsch Dermatol Ges"},{"key":"2024041719052917600_ljad484-B6","doi-asserted-by":"crossref","first-page":"1945","DOI":"10.1001\/jama.2020.4006","article-title":"Pathophysiology, clinical presentation, and treatment of psoriasis: a review","volume":"323","author":"Armstrong","year":"2020","journal-title":"JAMA"},{"key":"2024041719052917600_ljad484-B7","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1159\/000313825","article-title":"Time needed for treatment is the major predictor of quality of life in psoriasis","volume":"221","author":"Blome","year":"2010","journal-title":"Dermatology"},{"key":"2024041719052917600_ljad484-B8","doi-asserted-by":"crossref","first-page":"2057","DOI":"10.1007\/s13555-021-00620-x","article-title":"Characterizing outcomes and unmet needs among patients in the United States with mild-to-moderate plaque psoriasis using prescription topicals","volume":"11","author":"Gupta","year":"2021","journal-title":"Dermatol Ther (Heidelb)"},{"key":"2024041719052917600_ljad484-B9","doi-asserted-by":"crossref","first-page":"2200570","DOI":"10.1080\/09546634.2023.2200570","article-title":"Treatment satisfaction of patients with psoriasis with topical therapy in a real-world setting: unmet need for higher effectiveness","volume":"34","author":"Ninosu","year":"2023","journal-title":"J Dermatolog Treat"},{"key":"2024041719052917600_ljad484-B10","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1080\/09546634.2019.1675855","article-title":"Psoriasis patient preferences for topical drugs: a systematic review","volume":"32","author":"Svendsen","year":"2021","journal-title":"J Dermatolog Treat"},{"key":"2024041719052917600_ljad484-B11","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1007\/s00403-015-1613-8","article-title":"Patient-relevant treatment goals in psoriasis","volume":"308","author":"Blome","year":"2016","journal-title":"Arch Dermatol Res"},{"key":"2024041719052917600_ljad484-B12","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1007\/s00403-009-0928-8","article-title":"The Patient Benefit Index: a novel approach in patient-defined outcomes measurement for skin diseases","volume":"301","author":"Augustin","year":"2009","journal-title":"Arch Dermatol Res"},{"key":"2024041719052917600_ljad484-B13","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1007\/s00403-012-1256-y","article-title":"Validation of the Patient Benefit Index for the assessment of patient-relevant benefit in the treatment of psoriasis","volume":"304","author":"Feuerhahn","year":"2012","journal-title":"Arch Dermatol Res"},{"key":"2024041719052917600_ljad484-B14","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1111\/bjd.21593","article-title":"Measuring patient-relevant benefits in the treatment of psoriasis with the Patient Benefit Index: development and preliminary validation of a 10-item short form","volume":"187","author":"Blome","year":"2022","journal-title":"Br J Dermatol"},{"key":"2024041719052917600_ljad484-B15","doi-asserted-by":"crossref","DOI":"10.3390\/jcm10245836","article-title":"Identifying epidermolysis bullosa patient needs and perceived treatment benefits: an explorative study using the Patient Benefit Index","volume":"10","author":"Schr\u00e4der","year":"2021","journal-title":"J Clin Med"},{"key":"2024041719052917600_ljad484-B16","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1007\/s40801-021-00227-w","article-title":"Unmet personal patient needs in psoriasis patients with low disease activity on adalimumab, etanercept or ustekinumab","volume":"8","author":"van Muijen","year":"2021","journal-title":"Drugs Real World Outcomes"},{"key":"2024041719052917600_ljad484-B17","doi-asserted-by":"crossref","first-page":"e0235091","DOI":"10.1371\/journal.pone.0235091","article-title":"Sex-related impairment and patient needs\/benefits in anogenital psoriasis: difficult-to-communicate topics and their impact on patient-centred care","volume":"15","author":"Da Silva N, Augustin M, Langenbruch A","year":"2020","journal-title":"PLoS One"},{"key":"2024041719052917600_ljad484-B18","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1111\/jdv.15324","article-title":"Gender and age significantly determine patient needs and treatment goals in psoriasis \u2013 a lesson for practice","volume":"33","author":"Maul","year":"2019","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"2024041719052917600_ljad484-B19","doi-asserted-by":"crossref","first-page":"1543","DOI":"10.1111\/jdv.17278","article-title":"Impact of baricitinib in combination with topical steroids on atopic dermatitis symptoms, quality of life and functioning in adult patients with moderate-to-severe atopic dermatitis from the BREEZE-AD7 phase 3 randomized trial","volume":"35","author":"Wollenberg","year":"2021","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"2024041719052917600_ljad484-B20","doi-asserted-by":"crossref","first-page":"1686","DOI":"10.1111\/jdv.17109","article-title":"Patient-reported outcomes with risankizumab versus fumaric acid esters in systemic therapy-na\u00efve patients with moderate to severe plaque psoriasis: a phase 3 clinical trial","volume":"35","author":"Tha\u00e7i","year":"2021","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"2024041719052917600_ljad484-B21","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1111\/jdv.16632","article-title":"Secukinumab treatment leads to normalization of quality of life and disease symptoms in psoriasis patients with or without prior systemic psoriasis therapy: the PROSE study results","volume":"35","author":"Augustin","year":"2021","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"2024041719052917600_ljad484-B22","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1111\/jdv.13823","article-title":"Quality of life and patient benefit following transition from methotrexate to ustekinumab in psoriasis","volume":"31","author":"Augustin","year":"2017","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"2024041719052917600_ljad484-B23","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1080\/09546634.2018.1544410","article-title":"Patient preferences for attributes of topical anti-psoriatic medicines","volume":"30","author":"Vasconcelos","year":"2019","journal-title":"J Dermatolog Treat"},{"volume-title":"Qualitative Research & Evaluation Methods: Integrating Theory and Practice","year":"2015","author":"Patton","key":"2024041719052917600_ljad484-B24"},{"key":"2024041719052917600_ljad484-B25","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1159\/000195174","article-title":"Assessing the value of supportive skin care: development and validation of an instrument for evaluating patient-relevant benefit","volume":"218","author":"Augustin","year":"2009","journal-title":"Dermatology"},{"key":"2024041719052917600_ljad484-B26","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1007\/s00403-016-1648-5","article-title":"Development and validation of the Patient Benefit Index for the dermatocosmetic treatment of aged skin","volume":"308","author":"Lohrberg","year":"2016","journal-title":"Arch Dermatol Res"},{"key":"2024041719052917600_ljad484-B27","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1111\/j.1365-2230.1994.tb01167.x","article-title":"Dermatology Life Quality Index (DLQI)\u00a0\u2013 a simple practical measure for routine clinical use","volume":"19","author":"Finlay","year":"1994","journal-title":"Clin Exp Dermatol"},{"key":"2024041719052917600_ljad484-B28","first-page":"997","article-title":"The Dermatology Life Quality Index 1994\u20132007: a comprehensive review of validation data and clinical results","volume":"159","author":"Basra","year":"2008","journal-title":"Br J Dermatol"},{"key":"2024041719052917600_ljad484-B29","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1159\/000250839","article-title":"Severe psoriasis \u2013 oral therapy with a new retinoid","volume":"157","author":"Fredriksson","year":"1978","journal-title":"Dermatologica"},{"issue":"Suppl. 2","key":"2024041719052917600_ljad484-B30","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1111\/j.1468-3083.2009.03562.x","article-title":"What are the best outcome measures for assessing plaque psoriasis severity? A systematic review of the literature","volume":"24","author":"Puzenat","year":"2010","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"2024041719052917600_ljad484-B31","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1007\/s40257-020-00521-3","article-title":"Treatment goals in psoriasis: which outcomes matter most?","volume":"21","author":"Svoboda","year":"2020","journal-title":"Am J Clin Dermatol"},{"issue":"Suppl. 4","key":"2024041719052917600_ljad484-B32","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1111\/j.1468-3083.2011.04060.x","article-title":"Maximizing patient adherence for optimal outcomes in psoriasis","volume":"25","author":"Bewley","year":"2011","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"2024041719052917600_ljad484-B33","doi-asserted-by":"crossref","first-page":"559","DOI":"10.5021\/ad.2017.29.5.559","article-title":"Adherence to topical therapies for the treatment of psoriasis: surveys of physicians and patients","volume":"29","author":"Choi","year":"2017","journal-title":"Ann Dermatol"},{"key":"2024041719052917600_ljad484-B34","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1177\/1203475418773736","article-title":"Canadian patients\u2019 preferences in topical psoriasis care: insights from the PROPEL surveys","volume":"22","author":"Vender","year":"2018","journal-title":"J Cutan Med Surg"}],"container-title":["British Journal of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/bjd\/advance-article-pdf\/doi\/10.1093\/bjd\/ljad484\/56657800\/ljad484.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/bjd\/article-pdf\/190\/5\/701\/57262196\/ljad484.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/bjd\/article-pdf\/190\/5\/701\/57262196\/ljad484.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,4,17]],"date-time":"2024-04-17T21:21:35Z","timestamp":1713388895000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/bjd\/article\/190\/5\/701\/7517235"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1,12]]},"references-count":34,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2024,1,12]]},"published-print":{"date-parts":[[2024,4,17]]}},"URL":"https:\/\/doi.org\/10.1093\/bjd\/ljad484","relation":{},"ISSN":["0007-0963","1365-2133"],"issn-type":[{"type":"print","value":"0007-0963"},{"type":"electronic","value":"1365-2133"}],"subject":[],"published-other":{"date-parts":[[2024,5]]},"published":{"date-parts":[[2024,1,12]]}}}